REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
REPLIGEN CORP (RGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 69.80 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2026-07-29
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-06-30 was 30.69K shares, a 207.81% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-03-31 was 39.11K shares, a 40.42% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-12-31 was 12.03K shares, a 124.95% increase year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-09-30 was 4.14K shares, a 68.19% decline year-over-year.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2025 was 53.99K shares, a 38.51% decline from fiscal 2024.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2024 was 87.80K shares, a 19.65% increase from fiscal 2023.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2023 was 73.38K shares, a 18.83% increase from fiscal 2022.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 61.75K shares, a 81.02% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 30.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | 69.80K shares 10-Q · filed 2026-07-29 | 81.83K shares derived: sum of 3 quarters · filed 2026-07-29 | 85.97K shares derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | 39.11K shares 10-Q · filed 2026-05-06 | 51.14K shares derived: sum of 2 quarters · filed 2026-05-06 | 55.27K shares derived: sum of 3 quarters · filed 2026-05-06 | 65.25K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 12.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 16.16K shares derived: sum of 2 quarters · filed 2026-02-26 | 26.14K shares derived: sum of 3 quarters · filed 2026-02-26 | 53.99K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 4.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 14.11K shares derived: sum of 2 quarters · filed 2025-11-04 | 41.96K shares 10-Q · filed 2025-11-04 | 47.31K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 9.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 37.82K shares 10-Q · filed 2025-08-07 | 43.17K shares derived: sum of 3 quarters · filed 2025-08-07 | 56.18K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 27.85K shares 10-Q · filed 2025-04-29 | 33.20K shares derived: sum of 2 quarters · filed 2025-04-29 | 46.21K shares derived: sum of 3 quarters · filed 2025-04-29 | 94.68K shares derived: sum of 4 quarters · filed 2025-04-29 |
| 2024-12-31 | 5.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | 18.36K shares derived: sum of 2 quarters · filed 2025-03-14 | 66.83K shares derived: sum of 3 quarters · filed 2025-03-14 | 87.80K shares 10-K · filed 2025-03-14 |
| 2024-09-30 | 13.01K shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-18 | 61.48K shares derived: sum of 2 quarters · filed 2024-11-18 | 82.45K shares 10-Q · filed 2024-11-18 | 101.91K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2024-06-30 | 48.47K shares derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | 69.44K shares 10-Q/A · filed 2024-11-18 | 88.90K shares derived: sum of 3 quarters · filed 2024-11-18 | 103.42K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2024-03-31 | 20.97K shares 10-Q/A · filed 2024-11-18 | 40.43K shares derived: sum of 2 quarters · filed 2024-11-18 | 54.95K shares derived: sum of 3 quarters · filed 2024-11-18 | 72.82K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-12-31 | 19.46K shares derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-11-18 | 33.98K shares derived: sum of 2 quarters · filed 2024-11-18 | 51.85K shares derived: sum of 3 quarters · filed 2024-11-18 | 73.38K shares 10-K/A · filed 2024-11-18 |
| 2023-09-30 | 14.52K shares derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | 32.39K shares derived: sum of 2 quarters · filed 2024-11-18 | 53.92K shares 10-Q/A · filed 2024-11-18 | 72.28K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | 17.87K shares derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | 39.40K shares 10-Q/A · filed 2024-11-18 | 57.76K shares derived: sum of 3 quarters · filed 2024-11-18 | 76.30K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | 21.53K shares 10-Q/A · filed 2024-11-18 | 39.89K shares derived: sum of 2 quarters · filed 2024-11-18 | 58.43K shares derived: sum of 3 quarters · filed 2024-11-18 | 74.81K shares derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | 18.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | 36.90K shares derived: sum of 2 quarters · filed 2023-02-22 | 53.28K shares derived: sum of 3 quarters · filed 2023-02-22 | 61.75K shares 10-K · filed 2023-02-22 |
| 2022-09-30 | 18.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 34.92K shares derived: sum of 2 quarters · filed 2022-11-01 | 43.39K shares 10-Q · filed 2022-11-01 | |
| 2022-06-30 | 16.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | 24.85K shares 10-Q · filed 2022-08-02 | ||
| 2022-03-31 | 8.47K shares 10-Q · filed 2022-04-27 | |||
| 2021-12-31 | 34.11K shares 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |